BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	6	19	86	602	569	1,126
Market Cap Growth	-78.51%	-78.51%	-85.65%	5.82%	-49.47%	327.27%
Enterprise Value	71	83	96	462	317	895
Last Close Price	2.03	5.98	47.20	343.68	325.28	739.20
PS Ratio	2.27	8.19	62.58	1605.17	-	-
PB Ratio	-0.07	-0.22	-1.53	7.84	2.57	5.45
P/TBV Ratio	-	-	-	7.84	2.57	5.45
EV/Sales Ratio	31.28	36.69	69.82	1233.33	-	-
Debt / Equity Ratio	-1.23	-1.23	-1.79	1.22	0.01	0.01
Asset Turnover	-	-	0.01	0.00	-	-
Inventory Turnover	-	-	0.63	-	-	-
Quick Ratio	-	-	2.40	5.90	13.98	18.00
Current Ratio	-	-	2.65	6.17	14.21	18.33
Return on Equity (ROE)	-	-	-1766.94%	-111.08%	-49.93%	-70.35%
Return on Assets (ROA)	-	-	-74.95%	-44.81%	-29.10%	-40.13%
Return on Capital (ROIC)	-126.15%	-126.15%	-97.23%	-50.73%	-31.02%	-43.59%
Earnings Yield	-946.52%	-321.18%	-207.35%	-27.54%	-18.80%	-7.30%
FCF Yield	-	-179.52%	-22.51%	-14.52%	-5.92%
Buyback Yield / Dilution	-39.24%	-39.24%	-3.98%	-6.23%	-21.63%	-33.11%

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q